Chinese biotech investor Viroad acquired Gilupi, a Potsdam, Germany-based biotech company.
The amount of the deal was not disclosed.
Investors Aurelia, High-Tech Gründerfonds (HTGF), KfW, ILB, the venture capital fund of the Sparkassen of Brandenburg, and some business angels sold their shares to Viroad, which was the largest investor and shareholder of Gilupi since December 2012.
Due to the takeover, the company will continue the development of its medical products and to diversify their range of products through in-vitro diagnostics.
developing and manufacturing personalized cancer diagnostics. At the same time, the company will access to the Chinese market.
Founded in 2006 by Managing Director Dr. Jens Pfannkuche, Gilupi is a medical device company with focus on the development and production of new innovative products for the in vivo isolation of circulating tumor cells (CTCs). These products are based on a unique patented technology, The GILUPI CellCollector®, which consists of a thin, gold-coated stainless steel wire. The tip is coated with a biocompatible hydrogel with bound antibodies which are specifically directed against surface proteins of CTC. Once CTCs flow by, they are bound to the antibodies and can be isolated from the blood of the patient for further diagnosis.